{"company":{"id":1988069,"name":"KymeraTx","domain":"kymeratx.com","url":"https://alion.io/company/kymeratx"},"section":"news","answer":"KymeraTx: 17 headlines on record, 2 headlines in the last 90 days.","figures":[{"label":"Headlines","value":"17"},{"label":"In 90 days","value":"2"},{"label":"Milestones","value":"0"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":17}],"news":[{"date":"2026-09-02","kind":"Press release","title":"Kymera Therapeutics to Participate in Upcoming September Investor Conferences","source":"The Manila Times","url":"https://manilatimes.net/2026/09/03/tmt-newswire/globenewswire/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences/2417438"},{"date":"2026-09-01","kind":"News","title":"Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat6-degrader-at-the-european-respiratory-society-and-european-academy-of-dermatology-venereology-congresses/"},{"date":"2026-08-05","kind":"News","title":"Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-announces-second-quarter-2026-financial-results-and-provides-a-business-update/"},{"date":"2026-07-27","kind":"News","title":"Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer/"},{"date":"2026-07-08","kind":"News","title":"Kymera CEO on fast-tracked eczema oral treatment trial","source":"CNBC","url":"https://cnbc.com/video/2026/07/07/kymera-ceo-on-fast-tracked-eczema-oral-treatment-trial.html"},{"date":"2026-06-25","kind":"News","title":"Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-621-in-atopic-dermatitis-with-topline-data-by-year-end-2026/"},{"date":"2026-06-24","kind":"News","title":"Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-board-of-directors/"},{"date":"2026-06-09","kind":"News","title":"Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-announces-first-participant-dosed-in-phase-1-trial-of-oral-irak4-degrader-kt-485-and-milestone-achievement-under-sanofi-collaboration/"},{"date":"2026-06-08","kind":"News","title":"Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-appoints-penny-carlson-as-senior-vice-president-development-operations/"},{"date":"2026-04-30","kind":"News","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","source":"digmedia","url":"https://investingnews.com/kymera-therapeutics-announces-first-quarter-2026-financial-results-and-provides-a-business-update/"},{"date":"2026-04-24","kind":"News","title":"FDA grants fast track designation to KT-621 for moderate to severe eosinophilic asthma","source":"healio.com","url":"https://healio.com/news/allergy-asthma/20260424/fda-grants-fast-track-designation-to-kt621-for-moderate-to-severe-eosinophilic-asthma"},{"date":"2026-04-23","kind":"News","title":"Kymera Therapeutics to Announce First Quarter 2026 Financial Results and Host Video Conference Call KYMR Stock News","source":"Quiver Quantitative","url":"https://quiverquant.com/news/Kymera+Therapeutics+to+Announce+First+Quarter+2026+Financial+Results+and+Host+Video+Conference+Call"},{"date":"2025-12-09","kind":"News","title":"Kymera readout hints at new era for degraders in immunology","source":"BioCentury","url":"https://biocentury.com/article/657808"},{"date":"2025-12-08","kind":"News","title":"Kymera drug positioned to rival Sanofi and Regeneron's Dupixent succeeds in early-stage eczema trial","source":"STAT","url":"https://statnews.com/2025/12/08/kymera-kt-621-clinical-trial-results-atopic-dermatitis-challenge-dupixent/"},{"date":"2025-11-24","kind":"Press release","title":"Kymera Therapeutics to Participate in Upcoming December Investor Conferences","source":"The Manila Times","url":"https://manilatimes.net/2025/11/24/tmt-newswire/globenewswire/kymera-therapeutics-to-participate-in-upcoming-december-investor-conferences/2230294"},{"date":"2025-11-03","kind":"Press release","title":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences","source":"The Manila Times","url":"https://manilatimes.net/2025/11/03/tmt-newswire/globenewswire/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences/2214198"},{"date":"2025-10-17","kind":"News","title":"Matching degrader chemistry to the problem: The BioCentury Show","source":"BioCentury","url":"https://biocentury.com/article/657297/matching-degrader-chemistry-to-the-problem-the-biocentury-show"}],"as_of":"2026-11-14","cite":"KymeraTx, News. Alion, Nov 14, 2026. https://alion.io/company/kymeratx/news","html_url":"https://alion.io/company/kymeratx/news","json_url":"https://alion.io/company/kymeratx/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-14T04:51:32Z"}}